


Please type a plus sign (+) inside this box → +



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1 of 1

### Complete if Known

Application Number	09/857,000
Filing Date	September 7, 2001
First Named Inventor	PHILIPPE CLAIR ET AL.
Group Art Unit	1656
Examiner Name	KAM, CHIH MIN

Attorney Docket Number

03-520

### OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		ROUSSELLE, C., ET AL., "New Advances in the Transport of Doxorubicin Through The Blood-Brain-Barrier by a Peptide Vector-Mediated Strategy", Mol. Pharmacol., 57, 679 (2000).	
		ROUSSELLE, C., ET AL., "Enhanced Delivery of Doxorubicin into the Brain Via a Peptide-Vector-Mediated Strategy: Saturation Kinetics and Specificity", J. Pharmacol. Exp Ther., 296, 124 (2001).	
		BLANC, E., ET AL., "Peptide-Vector Strategy Bypasses P-Glycoprotein Efflux, and Enhances Brain Transport and Solubility of Paclitaxel", Anticancer Drugs., 15, 947 (2004).	
		ROUSSELLE, C., ET AL., "Improved Brain Delivery of Benzylpenicillin with a Peptide-Vector-Mediated Strategy", J Drug Target., 10, 309 (2002).	
		TEMSAMANI, J., ET AL., "Improved Brain Uptake and Pharmacological Activity Profile of Morphine-6-Glucuronide Using a Peptide Vector-Mediated Strategy", J Pharmacol. Exp Ther., 313, 712, (2005).	
		ROUSSELLE, C., ET AL., "Improved Brain Uptake and Pharmacological Activity of Dalargin Using a Peptide-Vector Mediated Strategy", J Pharmacol. Exp Ther., 306, 371 (2003).	

Examiner  
Signature

Date  
Considered

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.